Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid

Amyloid Angiopathy Clinical Trial

Official title: Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid

Status Completed

Clinical Trial Summary

The cerebral amyloïd angiopathy ( AAC) is a disease characterized by deposits of beta-amyloid peptids in the walls of the arteries of young and average calibre of the brain and the leptomeninx. The incidence of the AAC increases strongly with the age and represents a major cause of spontaneous brain haemorrhage to people over 60. The main demonstration is the lobar brain haemorrhage, the other ones are bleedings under arachnoid cortical and microbleedings leading to cognitive decline.

Anatomical studies reported the presence of cortical infarcts in patients having amyloïd deposits suggesting an association between asymptomatic cortical cerebral infarcts and AAC.

However prevalence and meaning of these infarcts in patients having an AAC remain badly known because of studies on low number of patients and the rarity of radiological analyses of these infarcts .A better knowledge of these asymptomatic cortical infarcts would allow to dread better cognitive disorders(confusions) presented by these patients, and to develop preventive strategies.

Besides, the risk factors of severity of the AAC are little studied.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Amyloid Angiopathy
• Amyloidosis
• Cerebral Infarction
• Infarction

• NCT number: NCT03262246
• Study type: Observational
• Source: Groupe Hospitalier Paris Saint Joseph
• Status: Completed
• Start date: June 2, 2016
• Completion date: December 31, 2018